drugset / Trial / NCT00073138
A Study of ABT-751 in Patients With Colorectal Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with colorectal cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.
Timeline
- Start
- 2003-08
- Primary completion
- —
- Completion
- 2005-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABT-751 | Other / unclassified | — | Oral |